BACKGROUND: Mutations in the recombinase-activating genes 1 and 2 (RAG1, RAG2) cause a spectrum of phenotypes, ranging from severe combined immune deficiency to combined immune deficiency with immune ...

The FDA in January approved Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan (Datroway) for unresectable or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2 ...